Phase I clinical trial dose escalation - 4th cohort
Sep 09, 2015EVENTSHit 1379
The third cohort (100 mg) in dose escalation of Phase I clinical trial to evaluate the safety was finished successfully. The safety monitoring committee (SMC) recommended a dose escalation to the next level (140 mg). Three clinical sites in the USA started recruitment of patients with solid tumor for the forth cohort.
|Next||Collaboration with ANRT|
|Previous||Announcement: 2nd annual general meeting of stockholders|